HR and neoplasm: For example, recruitment to TRAK-ER (NCT04985266) is ongoing through the Royal Marsden NHS Foundation Trust, which will investigate the benefit of adjuvant therapy on patients with HR+/HER2− EBC with detectable ctDNA using an alternative method of tumor-informed ctDNA assessment.